BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

Autor: Richard A. Scolyer, Victoria Atkinson, David E. Gyorki, Duncan Lambie, Sandra O'Toole, Robyn P.M. Saw, Benhur Amanuel, Christopher M. Angel, Alison E. Button-Sloan, Matteo S. Carlino, Sydney Ch'ng, Andrew J. Colebatch, Dariush Daneshvar, Inês Pires da Silva, Tamara Dawson, Peter M. Ferguson, Erwin Foster-Smith, Stephen B. Fox, Anthony J. Gill, Ruta Gupta, Michael A. Henderson, Angela M. Hong, Julie R. Howle, Louise A. Jackett, Craig James, C. Soon Lee, Alistair Lochhead, Daphne Loh, Grant A. McArthur, Catriona A. McLean, Alexander M. Menzies, Omgo E. Nieweg, Blake H. O'Brien, Thomas E. Pennington, Alison J. Potter, Saurabh Prakash, Robert V. Rawson, Rebecca L. Read, Michael A. Rtshiladze, Kerwin F. Shannon, B. Mark Smithers, Andrew J. Spillane, Jonathan R. Stretch, John F. Thompson, Paul Tucker, Alexander H.R. Varey, Ricardo E. Vilain, Benjamin A. Wood, Georgina V. Long
Rok vydání: 2022
Předmět:
Zdroj: Pathology. 54:6-19
ISSN: 0031-3025
DOI: 10.1016/j.pathol.2021.11.002
Popis: Targeted therapy (BRAF inhibitor plus MEK inhibitor) is now among the possible treatment options for patients with BRAF mutation-positive stage III or stage IV melanoma. This makes prompt BRAF mutation testing an important step in the management of patients diagnosed with stage III or IV melanoma; one that can help better ensure that the optimal choice of systemic treatment is initiated with minimal delay. This article offers guidance about when and how BRAF mutation testing should be conducted when patients are diagnosed with melanoma in Australia. Notably, it recommends that pathologists reflexively order BRAF mutation testing whenever a patient is found to have American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) stage III or IV melanoma (i.e., any metastatic spread beyond the primary tumour) and that patient's BRAF mutation status is hitherto unknown, even if BRAF mutation testing has not been specifically requested by the treating clinician (in Australia, Medicare-subsidised BRAF
Databáze: OpenAIRE
Externí odkaz: